현대사료

016790KOSDAQ

48.5 / 100

Reference Date: 2026-10-23

Financial Score16.0 / 40

News Sentiment12.5 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Hyundai Sahyo expanded its biotechnology business by acquiring LS L&C in 2023, focusing on developing the ovarian cancer treatment candidate 'Oregovomab'. The company emphasizes immunotherapy research amid the pharmaceutical industry's high entry barriers and growth potential, temporarily pausing its metastatic breast cancer pipeline. It concurrently operates a feed business alongside its biotech initiatives.

Number of Employees

68people

Average Salary

56.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

43.22Industry Average 15.000.0Point

2.9x industry avg (risky)

PBR

2.45Industry Average 1.200.0Point

2.0x industry avg (risky)

ROE

5.30Industry Average 8.002.5Point

Below industry avg

Debt Ratio

11.45Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼16.0% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲107.8% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 555.8% (declining, 2yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position4.0Point

52w mid range (50%)

Current 994Won52-week high 99452-week low 994

1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-10-14